Journal
NEURO-ONCOLOGY
Volume 15, Issue 8, Pages 972-978Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/not088
Keywords
adaptive; Bayesian; biomarker; clinical trials; glioblastoma
Categories
Funding
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate end-points. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available